Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
21.45 (1y: +51%)
Market Cap 1.51 B P/E(ttm) 17.30
Enterprise Value 1.31 B P/B 2.60
WX- NYSE (USA)
WuXi PharmaTech (Cayman), Inc.
Not Rated
Top Ranked Predictable Companies
$21.45
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry		 vs
history
Cash to Debt 3.541
WX's Cash to Debt is ranked higher than
61% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.95 vs. WX: 3.541 )
WX' s 10-Year Cash to Debt Range
Min: 0.33   Max: No Debt
Current: 3.54
Equity to Asset 0.779
WX's Equity to Asset is ranked higher than
84% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. WX: 0.779 )
WX' s 10-Year Equity to Asset Range
Min: -0.01   Max: 0.79
Current: 0.78
-0.01
0.79
Interest Coverage No Debt
WX's Interest Coverage is ranked higher than
83% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.60 vs. WX: No Debt )
WX' s 10-Year Interest Coverage Range
Min: 7   Max: No Debt
Current: No Debt
F-Score: 6
Z-Score: 7.23
M-Score: -2.73
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry		 vs
history
Operating margin (%) 17.90
WX's Operating margin (%) is ranked higher than
92% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. WX: 17.90 )
WX' s 10-Year Operating margin (%) Range
Min: -8.3   Max: 25.9
Current: 17.9
-8.3
25.9
Net-margin (%) 17.3
WX's Net-margin (%) is ranked higher than
96% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. WX: 17.3 )
WX' s 10-Year Net-margin (%) Range
Min: -25.3   Max: 27.2
Current: 17.3
-25.3
27.2
ROE (%) 15
WX's ROE (%) is ranked higher than
91% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. WX: 15 )
WX' s 10-Year ROE (%) Range
Min: -27.8   Max: 55
Current: 15
-27.8
55
ROA (%) 11.7
WX's ROA (%) is ranked higher than
93% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. WX: 11.7 )
WX' s 10-Year ROA (%) Range
Min: -19.1   Max: 18.2
Current: 11.7
-19.1
18.2
ROC (Joel Greenblatt) (%) 26.10
WX's ROC (Joel Greenblatt) (%) is ranked higher than
78% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. WX: 26.10 )
WX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -13.1   Max: 39.5
Current: 26.1
-13.1
39.5
Revenue Growth (%) 17
WX's Revenue Growth (%) is ranked higher than
95% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. WX: 17 )
WX' s 10-Year Revenue Growth (%) Range
Min: 8   Max: 139.8
Current: 17
8
139.8
EBITDA Growth (%) 15
WX's EBITDA Growth (%) is ranked higher than
96% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. WX: 15 )
WX' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 76.7
Current: 15
0
76.7
EPS Growth (%) 13.6
WX's EPS Growth (%) is ranked higher than
96% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. WX: 13.6 )
WX' s 10-Year EPS Growth (%) Range
Min: 0   Max: 31.6
Current: 13.6
0
31.6
» WX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

WX Guru Trades in Q2 2012

Julian Robertson 1,154,418 sh (+6.51%)
Mario Gabelli 198,000 sh (-4.12%)
Manning & Napier Advisors, Inc 4,328,351 sh (-15%)
Jim Simons 127,600 sh (-61.3%)
Steven Cohen 14,400 sh (-79.28%)
» More
Q3 2012

WX Guru Trades in Q3 2012

Julian Robertson 1,154,418 sh (unchged)
Jim Simons Sold Out
Steven Cohen Sold Out
Mario Gabelli 159,700 sh (-19.34%)
Manning & Napier Advisors, Inc 1,960,296 sh (-54.71%)
» More
Q4 2012

WX Guru Trades in Q4 2012

Bruce Kovner 24,400 sh (New)
Julian Robertson 1,154,418 sh (unchged)
Mario Gabelli 131,600 sh (-17.6%)
Manning & Napier Advisors, Inc 1,124,710 sh (-42.63%)
» More
Q1 2013

WX Guru Trades in Q1 2013

Jim Simons 45,900 sh (New)
John Hussman 40,000 sh (New)
Bruce Kovner 25,100 sh (+2.87%)
Mario Gabelli 128,600 sh (-2.28%)
Julian Robertson 1,036,618 sh (-10.2%)
Manning & Napier Advisors, Inc 203,970 sh (-81.86%)
» More
» Details

Insider Trades

Latest Guru Trades with WX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2013-03-31 New Buy0.03%$15.44 - $17.91 $ 21.4530%40000
Julian Robertson 2012-06-30 Add 6.51%0.28%$13.37 - $14.84 $ 21.4551%1154418
Julian Robertson 2012-03-31 Reduce -24.88%1.67%$11.43 - $15.39 $ 21.4568%1083818
Mario Gabelli 2011-12-31 Reduce -28.82%0.01%$10.78 - $13.92 $ 21.4580%250200
Julian Robertson 2011-09-30 Add 38.6%1.9%$11.56 - $17.26 $ 21.4551%1442806
George Soros 2011-06-30 Sold Out $16 - $18.89 $ 21.4524%0
Julian Robertson 2011-03-31 Add 5.71%0.24%$15.07 - $18.49 $ 21.4531%1095772
Mario Gabelli 2011-03-31 Reduce -64.06%0.11%$15.07 - $18.49 $ 21.4531%518000
George Soros 2011-03-31 New Buy0.05%$15.07 - $18.49 $ 21.4531%250000
Julian Robertson 2010-12-31 Add 30.12%0.99%$16.05 - $17.72 $ 21.4528%1036572
Julian Robertson 2010-09-30 New Buy4.58%$14.25 - $17.23 $ 21.4539%796621
Mario Gabelli 2010-09-30 Add 120.05%0.07%$14.25 - $17.23 $ 21.4539%1689100
Jean-Marie Eveillard 2010-09-30 Sold Out 0.05%$14.25 - $17.23 $ 21.4539%0
Julian Robertson 2010-06-30 Sold Out 3.68%$15.16 - $19.41 $ 21.4525%0
Mario Gabelli 2010-06-30 New Buy0.08%$15.16 - $19.41 $ 21.4525%767600
Jean-Marie Eveillard 2010-06-30 New Buy0.05%$15.16 - $19.41 $ 21.4525%450000
Premium More recent guru trades are included for Premium Members only!!
» Financial Charts

Peter Lynch Chart

Ratios

vs
industry		 vs
history
P/E(ttm) 17.30
WX's P/E(ttm) is ranked higher than
78% of the 85 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.70 vs. WX: 17.30 )
WX' s 10-Year P/E(ttm) Range
Min: 6.15   Max: 96.7
Current: 17.3
6.15
96.7
P/B 2.60
WX's P/B is ranked higher than
71% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.42 vs. WX: 2.60 )
WX' s 10-Year P/B Range
Min: 0.43   Max: 18.34
Current: 2.6
0.43
18.34
P/S 3.01
WX's P/S is ranked higher than
65% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.59 vs. WX: 3.01 )
WX' s 10-Year P/S Range
Min: 1.12   Max: 13.42
Current: 3.01
1.12
13.42
PFCF 24.50
WX's PFCF is ranked higher than
59% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.66 vs. WX: 24.50 )
WX' s 10-Year PFCF Range
Min: 10.85   Max: 96
Current: 24.5
10.85
96
EV-to-EBIT 14.1
WX's EV-to-EBIT is ranked higher than
72% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.29 vs. WX: 14.1 )
WX' s 10-Year EV-to-EBIT Range
Min: 1.4   Max: 146.9
Current: 14.1
1.4
146.9
PEG 0.3
WX's PEG is ranked higher than
97% of the 34 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.18 vs. WX: 0.3 )
WX' s 10-Year PEG Range
Min: 0.2   Max: 0.3
Current: 0.3
0.2
0.3
Shiller P/E 24.7
WX's Shiller P/E is ranked lower than
100% of the Companies
in the Global Diagnostics & Research industry.

( Industry Median: vs. WX: 24.7 )
WX' s 10-Year Shiller P/E Range
Min: 19.4   Max: 75.32
Current: 24.7
19.4
75.32

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 23.1
WX's Price/Net Cash is ranked lower than
54% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 13.90 vs. WX: 23.1 )
WX' s 10-Year Price/Net Cash Range
Min: 15.6   Max: 24.8
Current: 23.1
15.6
24.8
Price/Net Current Asset Value 15.1
WX's Price/Net Current Asset Value is ranked higher than
62% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.30 vs. WX: 15.1 )
WX' s 10-Year Price/Net Current Asset Value Range
Min: 10.7   Max: 86
Current: 15.1
10.7
86
Price/Tangible Book 2.8
WX's Price/Tangible Book is ranked higher than
75% of the 123 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. WX: 2.8 )
WX' s 10-Year Price/Tangible Book Range
Min: 1.8   Max: 7.7
Current: 2.8
1.8
7.7
Price/DCF (Projected) 1.6
WX's Price/DCF (Projected) is ranked higher than
57% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. WX: 1.6 )
WX' s 10-Year Price/DCF (Projected) Range
Min: 1.2   Max: 2.6
Current: 1.6
1.2
2.6
Price/Median PS Value 1.2
WX's Price/Median PS Value is ranked higher than
50% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. WX: 1.2 )
WX' s 10-Year Price/Median PS Value Range
Min: 0.5   Max: 3.7
Current: 1.2
0.5
3.7
Price/Peter Lynch Fair Value 0.7
WX's Price/Peter Lynch Fair Value is ranked higher than
83% of the 24 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. WX: 0.7 )
WX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.4   Max: 0.5
Current: 0.7
0.4
0.5
Price/Graham Number 1.5
WX's Price/Graham Number is ranked higher than
75% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. WX: 1.5 )
WX' s 10-Year Price/Graham Number Range
Min: 0.9   Max: 4.4
Current: 1.5
0.9
4.4
Earnings Yield (Greenblatt) 7.10
WX's Earnings Yield (Greenblatt) is ranked higher than
84% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. WX: 7.10 )
WX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.7   Max: 73.3
Current: 7.1
0.7
73.3
Forward Rate of Return (Yacktman) 67.46
WX's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. WX: 67.46 )
WX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.1   Max: 68.2
Current: 67.46
0.1
68.2

Business Description

WuXi PharmaTech, Inc. is a Cayman Islands holding company. It conducts substantially all of its business through five operating subsidiaries in China and one operating subsidiary in the United States. It is a pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. It provides a broad and integrated portfolio of laboratory and manufacturing services throughout the R&D process to its customers, which include many of the world's premier pharmaceutical, biotechnology and medical device companies. The Company's services are designed to assist its global customers in shortening the time and lowering the cost of pharmaceutical and medical-device R&D by providing cost-effective and efficient outsourcing solutions. It groups its operations into two segments: laboratory services and manufacturing services. The Company's laboratory services segment focused entirely on helping its customers discover and develop small-molecule pharmaceuticals through its services in discovery chemistry, medicinal chemistry, service biology, toxicology, formulation and bioanalytical and analytical services. The Company's manufacturing services segment focused on producing advanced intermediates and APIs for small-molecule pharmaceuticals used by its customers in clinical testing. Laboratory services are composed of discovery chemistry, discovery biology, DMPK/ADME, toxicology, process R&D, formulation, bioanalytical, biologics testing, medical device testing and development, and other related contract R&D services. The Company's current customers include all of the world's ten largest pharmaceutical companies. The pharmaceutical and biotechnology R&D outsourcing market remains highly fragmented. It competes with industry players in particular service areas- for example with Charles River Laboratories International, Inc., which recently partnered with Shanghai BioExplorer Co., Ltd., in the preclinical services area, and with Shanghai ChemPartner Co., Ltd. and BioDuro in the discovery chemistry area. Governmental agencies throughout the world, particularly in the United States, strictly regulate the pharmaceutical, biotechnology and medical device R&D process.
Company Website
Industry: Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ
Traded in other countries:3W11.Germany
» More Articles for NYSE:WX

Headlines

Articles On GuruFocus.com
comment on WX Sep 15 2012 
Stocks That Are Cheaper Than Julian Robertson Bought Jan 06 2012 
Stocks That Julian Robertson Keeps Buying Dec 23 2011 
Julian Robertson’s "smart idea, grounded on exhaustive research, followed by a big bet" Jun 24 2011 
Julian Robertson’s Tiger Management Q1 Portfolio Update May 16 2011 
Tiger Management Buys WX, CVC, THRX, Sells Apple Inc., Google Inc., Ebay Inc. Nov 15 2010 
WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services Dec 09 2008 

More From Our Partners
Apple TV Gets a Major Upgrade (Update 1) Jun 19 2013 - THESTREET

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK